Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Mirikizumab - Intravenous (IV) for Colitis, Ulcerative

Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. you would be assigned to the appropriate study prior to randomization to a treatment group.

Official registry: https://clinicaltrials.gov/study/NCT07483073 · Eli Lilly and Company · enrollment listed as 60

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), or LY4395089. The registry lists allocation as randomized. Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components.

They plan to enroll about 60 people at 71 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Interventions: Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089

Primary outcome (registry wording): Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 80 Years
  • Must have an established diagnosis of Ulcerative Colitis (UC) or Crohn's Disease (CD) for at least 3 month duration, which includes clinical and endoscopic evidence of UC or CD and a histopathology report that supports a diagnosis of UC or CD
  • Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5-9 points and Endoscopic Subscore (ES) greater than or equal to (≥) 2, confirmed by the central reader and rectal bleeding (RB)≥1
  • Must have demonstrated an inadequate response, loss of response, or intolerance to at least one of the following: corticosteroids, immunomodulators, or an advanced therapy for UC or CD
  • Have screening laboratory test results within the protocol specified parameters

Public study contact (from the registry)

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559

clinical_inquiry_hub@lilly.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

71 listed

+ 57 sites outside the US on the same record

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT07483073 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07483073?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07483073?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary